Pfizer/FDA: 95% Deception?


Swiss Policy Research - TRANSCEND Media Service

How the US FDA “fully approved” the Pfizer vaccine while still excluding product liability.

Full FDA approval? The Pfizer-Biontech covid vaccine

26 Aug 2021 – How can the US FDA “fully approve” the Pfizer covid vaccine without requiring product liability? As US biosafety expert Dr. Meryl Nass revealed, they simply split the Pfizer vaccine into two products: a branded product (“Comirnaty”), which received a full market license but is currently unavailable in the US (due to “insufficient stocks”); and an unbranded product (“Pfizer/Biontech vaccine”), which is widely available in the US but remains under the existing Emergency Use Authorization (EUA).

The result: they use the unavailable branded product to justify politically motivated vaccination mandates, but they may then deliver the unbranded product to avoid any liability for vaccine injuries (there is no liability under EUA, but there is full liability under a market license). It almost appears as though Pfizer and the FDA might be well aware of the incomplete and increasingly questionable safety and efficacy record of experimental covid vaccines.

As Dr. Nass notes, citizens pressured to take this vaccine against their will due to a federal, corporate or school mandate may demand to receive the (unavailable) branded product that comes with full liability in case of vaccine injury. To learn more about possible covid vaccine injuries, see the updated SPR Covid Vaccine Adverse Events overview. Globally, covid vaccines may already have killed or injured tens of thousands of people, including people at low risk of severe covid.

As a side note, former FDA Commissioner Scott Gottlieb happens to be a Pfizer board member.

See also: Dr. Peter Goetzsche: Deadly Medicines and Organized Crime (7 min. video)



Swiss Policy Research, founded in 2016, is an independent, nonpartisan and nonprofit research group investigating geopolitical propaganda in Swiss and international media. SPR is composed of independent academics that for personal and professional reasons prefer to protect their identities, and receives no external funding; there are no financial sponsors or backers. Our articles have been published or shared by numerous independent media outlets and journalists, among them Julian Assange, and have been translated into more than two dozen languages.

Go to Original –

Tags: , , , , , , , , , , , , , , , ,

Share this article:

DISCLAIMER: The statements, views and opinions expressed in pieces republished here are solely those of the authors and do not necessarily represent those of TMS. In accordance with title 17 U.S.C. section 107, this material is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes. TMS has no affiliation whatsoever with the originator of this article nor is TMS endorsed or sponsored by the originator. “GO TO ORIGINAL” links are provided as a convenience to our readers and allow for verification of authenticity. However, as originating pages are often updated by their originating host sites, the versions posted may not match the versions our readers view when clicking the “GO TO ORIGINAL” links. This site contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available in our efforts to advance understanding of environmental, political, human rights, economic, democracy, scientific, and social justice issues, etc. We believe this constitutes a ‘fair use’ of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes. For more information go to: If you wish to use copyrighted material from this site for purposes of your own that go beyond ‘fair use’, you must obtain permission from the copyright owner.

Comments are closed.